tively unimpressed by these agents. Therefore, ample market opportunity will remain at the end of the forecast period.
-To circumvent historical difficulties with regulatory approval, companies are designing early- and late-stage clinical trials more rigorously. Randomization of early-stage trials is critical, and the designation of overall survival (OS) as the primary endpoint of pivotal studies is mandatory.
-Key R&D trends include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and investigating new targets (i.e. FLT3) involved in the pathogenesis of AML.
-Despite the hype around FLT3 inhibitors, KOLs are unconvinced that these drugs will be successful as monotherapies in AML.
-Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
-Topline AML therapeutics market revenue from 2012–2017. Annual cost of therapy, and peak pipeline drug sales of drugs launching during this forecast period are included.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the AML therapeutics market.
-Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available.
-Analysis of the current and future market competition in the global AML therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
-Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and
Page: 1 2 3 4 5 6 7 8 9 Related medicine news :1
Copyright©2012 Vocus, Inc.
All rights reserved
. OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 20172
. Long-term neuropsychological impairment is common in acute lung injury survivors3
. Predictors identified for rehospitalization among post-acute stroke patients4
. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC5
. A microRNA prognostic marker identified in acute leukemia6
. 4 acute mushroom poisonings in 2 weeks7
. Scientists identify possible drug target for acute pancreatitis8
. Inhibitors of shuttle molecule show promise in acute leukemia9
. Is acetazolamide effective and safe for preventing acute mountain sickness?10
. A new target in acute myeloid leukemia11
. Implementing a therapeutic hypothermia program for post-cardiac arrest in acute care hospitals